ACADIA PHARMACEUTICALS INC. Accrued Income Taxes, Current
ACADIA PHARMACEUTICALS INC. (ACAD) had Accrued Income Taxes, Current of $8.46 million as of 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2024-08-07
- 2024-06-30: Accrued Income Taxes, Current $8.46M.
- 2024-03-31: Accrued Income Taxes, Current $7.59M.
- 2023-12-31: Accrued Income Taxes, Current $8.71M.
- 2023-09-30: Accrued Income Taxes, Current $8.45M.
| Period end | Accrued Income Taxes, Current |
|---|---|
| 2024-06-30 | $8.46M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $7.59M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $8.71M 10-Q · filed 2024-08-07 |
| 2023-09-30 | $8.45M 10-Q · filed 2023-11-03 |
| 2022-12-31 | $377.00K 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |